Infectious Diseases | |
|---|---|
| Study Name | Principal Investigator |
| TF-TF0023-201 – A Phase 2, Multicenter, Randomized, Double-blind (within dose), Placebo-controlled, Parallel-group, and Dose-range-finding Study to Evaluate the Efficacy and Safety of TF0023 Versus Placebo in Treatments for COVID-19 in Hospitalized Adults. Read more. |
Benjamin De La Rosa, MD |
| FREEDOM - Mount Sinai – COVID Anticoagulation Strategy Randomized Trial Read more. |
Suraj Saggar, DO |
| V3011902 – Veru – Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS) Read more. |
Benjamin De La Rosa, MD |
| VAT00002 – Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines with AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (two Monovalent and one Bivalent). Read more. |
Suraj Saggar, DO |
